Description
Humana Press Buprenorphine Therapy of Opiate Addiction 1st Editon 2012 Softbound by Pascal Kintz, Pierre Marquet
In Buprenorphine Therapy of Opiate Addiction, participating physicians and toxicologists summarize and evaluate their experiences with five years of intensive buprenorphine therapy. They cover all aspects of its use, including the pharmacology, conditions of delivery, risks from use with other psychoactive drugs, toxicology and related deaths, as well as its testing in blood, urine, tissue, and hair. Special attention is given to comparing the long-term care of opiate-dependent patients using high-dose buprenorphine vs methadone, and to explaining the differences in treatment, administration, and delivery. The authors also describe how buprenorphine is currently prescribed and monitored in France and Australia, and review all the latest advances in analytical techniques for the determination of buprenorphine and its metabolites in biological fluids and tissues. 1 Pharmacology of High-Dose Buprenorphine.- 1. Introduction.- 2. Pharmacokinetic Properties.- 3. Pharmacodynamic Properties.- 4. Administration Schedules.- 5. Clinical Effects of Buprenorphine.- 6. Conclusion.- References.- 2 Controlled Drug Administration Studies of High-Dose Buprenorphine in Humans.- 1. Introduction.- 2. Bioavailability.- 3. Dose-Effect Profiles.- 4. Abuse Liability.- 5. Toxicity.- 6. Safety and Abuse Liability of High-Dose Intravenous Buprenorphine.- 7. Conclusion.- References.- 3 High-Dose Buprenorphine for Treatment of Opioid Dependence.- 1. Introduction.- 2. Buprenorphine Solution vs Tablets.- 3. Efficacy of Buprenorphine vs Placebo: Clinical Trials.- 4. Efficacy of Buprenorphine vs Other Medications: Clinical Trials.- 5. Safety and Side Effects of Buprenorphine.- 6. Summary and Conclusions.- Acknowledgment.- References.- 4 Foreseeable Advantages and Limits of Buprenorphine-Naloxone Association.- 1. Introduction.- 2. Advantages of Buprenorphine-Naloxone Association.- 2.1.1. Epidemic of Pentazocine and Tripelennamine Abuse in the United States.- 2.1.2. Epidemic of Analgesic Buprenorphine Abuse in New Zealand.- 3. Limits of Buprenorphine-Naloxone Association.- 4. Conclusion.- References.- 5 Buprenorphine Maintenance Treatment in Primary Care: An Overview of the French Experience and Insight Into the Prison Setting.- 1. Introduction.- 2. Implementation of BMT Through French Primary Care System.- 3. Observable Effects of French Policy.- 4. Prison.- 5. Conclusion.- Acknowledgments.- References.- 6 Buprenorphine as a Viable Pharmacotherapy in Australia.- 1. Introduction.- 2. Buprenorphine.- 3. National Evaluation of Pharmacotherapies for Opioid Dependence.- 4. Conclusion.- Acknowledgments.- References.- 7 Separative Techniques for Determination of Buprenorphine.- 1. Introduction.- 2. Determination of Buprenorphine in Blood.- 3. Determination of Buprenorphine in Urine.- 4. Determination of Buprenorphine in Biological Tissues.- 5. Determination of Buprenorphine in Hair.- 6. Conclusion.- References.- 8 Buprenorphine-Related Deaths.- 1. Introduction.- 2. Forensic Aspects.- 3. Buprenorphine Fatalities.- 4. Conclusion.- References.- 9 Pharmacology of Opiates During Pregnancy and in Neonates.- 1. Introduction.- 2. Perinatal Pharmacokinetics of Opiates.- 3. Perinatal Pharmacodynamics of Opiates.- 4. Maintenance Treatments During Pregnancy.- References.- 10 Case Study of Neonates Born to Mothers Undergoing Buprenorphine Maintenance Treatment.- 1. Introduction.- 2. Clinical Findings.- 3. Toxicological Investigations.- 4. Discussion.- 5. Conclusion.- Acknowledgments.- References.- 11 Buprenorphine and Pregnancy: A Comparative, Multicenter Clinical Study of High-Dose Buprenorphine vs Methadone Maintenance.- 1. Introduction.- 2. Materials and Methods.- 3. Results.- 4. Discussion.- 5. Conclusion.- Acknowledgments.- References.